A recent phase II trial testing the efficacy of trastuzumab deruxtecan, an antibody–drug conjugate (ADC) drug composed of trastuzumab and topoisomerase I inhibitor, on patients with HER2-positive biliary tract cancer reported promising efficacy [74]. Here, ERBB2 is linked to biliary tract neoplasm.